Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) EPS (Basic) (2016 - 2026)

Cytosorbents filings provide 15 years of EPS (Basic) readings, the most recent being -$0.09 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 35.71% to -$0.09 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.13, a 65.79% increase, with the full-year FY2025 number at -$0.13, up 65.79% from a year prior.
  • EPS (Basic) hit -$0.09 in Q4 2025 for Cytosorbents, down from -$0.05 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.03 in Q2 2025 to a low of -$0.28 in Q3 2022.
  • Median EPS (Basic) over the past 5 years was -$0.12 (2021), compared with a mean of -$0.13.
  • Biggest five-year swings in EPS (Basic): tumbled 1331.96% in 2021 and later soared 137.5% in 2025.
  • Cytosorbents' EPS (Basic) stood at -$0.25 in 2021, then skyrocketed by 92.0% to -$0.02 in 2022, then plummeted by 500.0% to -$0.12 in 2023, then decreased by 16.67% to -$0.14 in 2024, then skyrocketed by 35.71% to -$0.09 in 2025.
  • The last three reported values for EPS (Basic) were -$0.09 (Q4 2025), -$0.05 (Q3 2025), and $0.03 (Q2 2025) per Business Quant data.